Adjuvant Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy

Yue-Lin Zhang; Chun-Hui Nie; Feng Chen; Tan-Yang Zhou; Guan-Hui Zhou; Tong-Yin Zhu; Sheng-Qun Chen; Xin-Hua Chen; Hong-Liang Wang; Bao-Quan Wang; Zi-Niu Yu; Li Jing; Zhi-Min He; Jun-Hui Sun

doi:10.3389/fonc.2020.01754

Adjuvant Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy

Front Oncol. 2020 Sep 2:10:1754. doi: 10.3389/fonc.2020.01754. eCollection 2020.

Authors

Yue-Lin Zhang^{1

2}, Chun-Hui Nie^{1

3}, Feng Chen⁴, Tan-Yang Zhou^{1

2}, Guan-Hui Zhou^{1

2}, Tong-Yin Zhu^{1

2}, Sheng-Qun Chen^{1

3}, Xin-Hua Chen^{1

2}, Hong-Liang Wang^{1

3}, Bao-Quan Wang^{1

2}, Zi-Niu Yu^{1

2}, Li Jing^{1

2}, Zhi-Min He^{1

3}, Jun-Hui Sun^{1

2

3}

Affiliations

¹ Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, China.
³ Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, China.
⁴ Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Abstract

Introduction: The care for patients with hepatocellular carcinoma (HCC) is challenging. This study is to evaluate the effect of adjuvant transarterial chemoembolization (TACE) for Barcelona Clinic Liver Cancer (BCLC) stage A HCC patients after hepatectomy.

Methods: Consecutive HCC patients with BCLC stage A, treated by hepatectomy alone (HA) or hepatectomy with TACE (HT), were retrospectively enrolled. Propensity score matching (PSM) was used to balance baseline differences. The recurrence-free survival (RFS) and overall survival (OS) were evaluated using the Kaplan-Meier. The impact of TACE on survival outcome was determined by Cox hazard regression.

Results: After PSM, 230 patients (115 HT and 115 HA) were enrolled in the analysis. The 1-, 3-, and 5-year RFS rates were 87.0, 63.5, and 50.4%, respectively, for the HT group, and 87.8, 67.0, and 58.3% for the HA group. The OS rates at 1-, 3-, and 5-year were 99.1, 93.9, and 87%, respectively, for the HT group, and 100, 92.2, and 88.7% for the HA group. No significant differences were seen in either the RFS (log-rank test, χ² = 0.891, p = 0.345) or OS (log-rank test, χ² = 0.146, p = 0.702) between the specific pairs of two groups. Cox regression identified that TACE was not the factor affecting RFS or OS (p = 0.399; HR 0.847; 95% CI 0.576-1.245 for RFS vs. p = 0.989; HR 0.995; 95% CI 0.471-2.100 for OS).

Conclusion: Our data indicate that TACE is not an effective intervention in the adjuvant setting for BCLC stage A HCC after hepatectomy.

Keywords: hepatectomy; hepatocellular carcinoma; recurrence; survival; transarterial chemoembolization.